Published • loading... • Updated
Ionis Pharmaceuticals (IONS) Stock Analysis: A Biotech Pioneer with 33% Upside Potential
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Ionis Pharmaceuticals (IONS) Stock Analysis: A Biotech Pioneer with 33% Upside Potential
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) is a frontrunner in the biotechnology sector, renowned for its pioneering RNA-targeted medicines. With a market capitalization of $12.51 billion, Ionis has carved a niche in the healthcare industry, focusing on treatments for rare and debilitating diseases. The company’s current stock price of $75.71, in conjunction with an average target price of $100.74 set by analysts, suggests a promising potential …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
